Pain Management Treatment Market to Catapult by 2018

Pain Management Treatment Market to Catapult by 2018 
NEW YORK, NY -- (Marketwire) -- 03/11/13 --
cites in its newly published "Pain Management Treatment Markets"
report that the pain management treatment market will catapult by
2018. For more information, visit: 
Pain management drugs, or analgesics, can be categorized into three
main modalities: acetaminophen, NSAIDs and opioids. Pain, meanwhile,
can be categorized into four main modalities: acute, chronic,
neuropathic and nociceptive. The pain management market is currently
valued at $52 billion. Growing at a rate of 20%, the opioid segment
will constitute a full 43% of the pain management market by 2018.
Although the U.S. market will only increase modestly to $21.8
billion, it remains the largest market by far throughout the forecast
The "Pain Management Treatment Markets" report covers: 

--  CGRP antagonists
--  CB2 agonists
--  Sodium channel modulators
--  Calcium channel modulators
--  NMDA antagonists
--  P2x receptors
--  Trp channels
--  TrpV1 blockers
--  FAAH inhibitors
--  Novel opioids
--  Extended release formulations
--  Transdermal formulations

The "Pain Management Treatment Markets" report examines companies
manufacturing pain management equipment and supplies in the world.
Companies covered include: Abbott, AcelRx, Acura, Afferent, Algiax,
Arcion, Astellas, BioDelivery Sciences, Cara, Cephalon, Convergence,
Cytogel, DURECT, Egalet, Eli Lilly, Endo, Gruenenthal, Hospira, iMed,
Johnson & Johnson, KemPharm, Mallinckrodt, NeurAxon, NeurogesX,
Newron, Novartis, Nuvo, Pacira, Pain Therapeutics, Pfizer, Purdue,
QRx, Relevare, Relmada, Spinifex, Xenon, Xenoport, Zalicus and
Detailed charts with sales forecasts and marketshare data are
included. For more information, visit: 
About is a global leader in the biotechnology,
healthcare and life sciences market research publishing. For more
information, please visit  
Important Notice 
The statements contained in this news release that are
forward-looking are based on current expectations that are subject to
a number of uncertainties and risks, and actual results may differ
Media Relations
Press spacebar to pause and continue. Press esc to stop.